Luc Biedermann

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7575591/publications.pdf

Version: 2024-02-01

57631 22102 13,427 146 44 113 citations h-index g-index papers 149 149 149 6846 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Eosinophilic esophagitis: Updated consensus recommendations for children and adults. Journal of Allergy and Clinical Immunology, 2011, 128, 3-20.e6.	1.5	1,839
2	Eosinophilic Esophagitis in Children and Adults: A Systematic Review and Consensus Recommendations for Diagnosis and Treatment. Gastroenterology, 2007, 133, 1342-1363.	0.6	1,547
3	Guidelines on eosinophilic esophagitis: evidenceâ€based statements and recommendations for diagnosis and management in children and adults. United European Gastroenterology Journal, 2017, 5, 335-358.	1.6	718
4	Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the AGREE Conference. Gastroenterology, 2018, 155, 1022-1033.e10.	0.6	712
5	Natural history of primary eosinophilic esophagitis: a follow-up of 30 adult patients for up to 11.5 years. Gastroenterology, 2003, 125, 1660-1669.	0.6	673
6	Delay in Diagnosis of Eosinophilic Esophagitis Increases Risk for Stricture Formation in a Time-Dependent Manner. Gastroenterology, 2013, 145, 1230-1236.e2.	0.6	580
7	Idiopathic eosinophilic esophagitis is associated with a TH2-type allergic inflammatory response. Journal of Allergy and Clinical Immunology, 2001, 108, 954-961.	1.5	511
8	Budesonide Is Effective in Adolescent and Adult Patients With Active Eosinophilic Esophagitis. Gastroenterology, 2010, 139, 1526-1537.e1.	0.6	477
9	Long-Term Budesonide Maintenance Treatment Is Partially Effective for Patients With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2011, 9, 400-409.e1.	2.4	348
10	Escalating incidence of eosinophilic esophagitis: AÂ20-year prospective, population-based study in Olten County, Switzerland. Journal of Allergy and Clinical Immunology, 2011, 128, 1349-1350.e5.	1.5	313
11	Smoking Cessation Induces Profound Changes in the Composition of the Intestinal Microbiota in Humans. PLoS ONE, 2013, 8, e59260.	1.1	305
12	Proton pump inhibitor-responsive oesophageal eosinophilia: an entity challenging current diagnostic criteria for eosinophilic oesophagitis. Gut, 2016, 65, 524-531.	6.1	279
13	Esophageal Dilation in Eosinophilic Esophagitis: Effectiveness, Safety, and Impact on the Underlying Inflammation. American Journal of Gastroenterology, 2010, 105, 1062-1070.	0.2	277
14	Symptoms Have Modest Accuracy in Detecting Endoscopic and Histologic Remission in Adults With Eosinophilic Esophagitis. Gastroenterology, 2016, 150, 581-590.e4.	0.6	251
15	Development and Validation of a Symptom-Based Activity Index for Adults With Eosinophilic Esophagitis. Gastroenterology, 2014, 147, 1255-1266.e21.	0.6	221
16	Eosinophilic Esophagitis: Analysis of Food Impaction and Perforation in 251 Adolescent and Adult Patients. Clinical Gastroenterology and Hepatology, 2008, 6, 598-600.	2.4	217
17	Eosinophilic esophagitis is frequently associated with IgE-mediated allergic airway diseases. Journal of Allergy and Clinical Immunology, 2005, 115, 1090-1092.	1.5	184
18	RPC4046, a Monoclonal Antibody Against IL13, ReducesÂHistologic and Endoscopic Activity in Patients With Eosinophilic Esophagitis. Gastroenterology, 2019, 156, 592-603.e10.	0.6	182

#	Article	IF	CITATIONS
19	Corticosteroid-dependent eosinophilic oesophagitis: azathioprine and 6-mercaptopurine can induce and maintain long-term remission. European Journal of Gastroenterology and Hepatology, 2007, 19, 865-869.	0.8	174
20	Efficacy of Budesonide Orodispersible Tablets as Induction Therapy for Eosinophilic Esophagitis in a Randomized Placebo-Controlled Trial. Gastroenterology, 2019, 157, 74-86.e15.	0.6	170
21	The intestinal microbiota: its role in health and disease. European Journal of Pediatrics, 2015, 174, 151-167.	1.3	144
22	Smoking Cessation Alters Intestinal Microbiota. Inflammatory Bowel Diseases, 2014, 20, 1496-1501.	0.9	142
23	Diagnosis and Treatment of Eosinophilic Esophagitis. Gastroenterology, 2018, 154, 346-359.	0.6	110
24	Bilberry ingestion improves disease activity in mild to moderate ulcerative colitis â€" An open pilot study. Journal of Crohn's and Colitis, 2013, 7, 271-279.	0.6	106
25	Long-Term Treatment of Eosinophilic Esophagitis With Swallowed Topical Corticosteroids: Development and Evaluation of a Therapeutic Concept. American Journal of Gastroenterology, 2017, 112, 1527-1535.	0.2	105
26	Pain in IBD Patients: Very Frequent and Frequently Insufficiently Taken into Account. PLoS ONE, 2016, 11, e0156666.	1.1	104
27	ECCO Position Paper: Harmonization of the Approach to Ulcerative Colitis Histopathology. Journal of Crohn's and Colitis, 2020, 14, 1503-1511.	0.6	100
28	Colectomy Rates in Ulcerative Colitis are Low and Decreasing: 10-year Follow-up Data From the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2018, 12, 811-818.	0.6	88
29	Budesonide Orodispersible Tablets Maintain Remission in a Randomized, Placebo-Controlled Trial of Patients With Eosinophilic Esophagitis. Gastroenterology, 2020, 159, 1672-1685.e5.	0.6	88
30	Gender Differences in Inflammatory Bowel Disease. Digestion, 2020, 101, 98-104.	1.2	82
31	Bilberry-Derived Anthocyanins Modulate Cytokine Expression in the Intestine of Patients with Ulcerative Colitis. PLoS ONE, 2016, 11, e0154817.	1.1	71
32	Vegetarian or glutenâ€free diets in patients with inflammatory bowel disease are associated with lower psychological wellâ€being and a different gut microbiota, but no beneficial effects on the course of the disease. United European Gastroenterology Journal, 2019, 7, 767-781.	1.6	67
33	Maintenance Treatment Of Eosinophilic Esophagitis With Swallowed Topical Steroids Alters Disease Course Over A 5-Year Follow-up Period In Adult Patients. Clinical Gastroenterology and Hepatology, 2019, 17, 419-428.e6.	2.4	66
34	Association of Alterations in Intestinal Microbiota With Impaired Psychological Function in Patients With Inflammatory Bowel Diseases in Remission. Clinical Gastroenterology and Hepatology, 2020, 18, 2019-2029.e11.	2.4	64
35	Acute Herpes Simplex Viral Esophagitis Occurring in 5 Immunocompetent Individuals With Eosinophilic Esophagitis. ACG Case Reports Journal, 2016, 3, 165-168.	0.2	61
36	Nutrition in Inflammatory Bowel Disease. Digestion, 2020, 101, 120-135.	1.2	59

#	Article	IF	Citations
37	International Consensus Recommendations for Eosinophilic Gastrointestinal Disease Nomenclature. Clinical Gastroenterology and Hepatology, 2022, 20, 2474-2484.e3.	2.4	57
38	Effectiveness and Safety of Vedolizumab in Anti-TNF-NaÃ⁻ve Patients With Inflammatory Bowel Disease—A Multicenter Retrospective European Study. Inflammatory Bowel Diseases, 2018, 24, 2442-2451.	0.9	56
39	Minimally invasive biomarker studies in eosinophilic esophagitis. Annals of Allergy, Asthma and Immunology, 2018, 121, 218-228.	0.5	55
40	Risk factors for gallstones and kidney stones in a cohort of patients with inflammatory bowel diseases. PLoS ONE, 2017, 12, e0185193.	1.1	54
41	High Rates of Smoking Especially in Female Crohn's Disease Patients and Low Use of Supportive Measures to Achieve Smoking Cessation—Data from the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2015, 9, 819-829.	0.6	52
42	Long-term changes of bacterial and viral compositions in the intestine of a recovered $\langle i \rangle$ Clostridium difficile $\langle i \rangle$ patient after fecal microbiota transplantation. Journal of Physical Education and Sports Management, 2016, 2, a000448.	0.5	50
43	Eosinophilic Gastroenteritis: Clinical Manifestation, Natural Course, and Evaluation of Treatment with Corticosteroids and Vedolizumab. Digestive Diseases and Sciences, 2019, 64, 2231-2241.	1.1	49
44	The Natural History and Complications of Eosinophilic Esophagitis. Thoracic Surgery Clinics, 2011, 21, 575-587.	0.4	45
45	Monitoring colonoscopy withdrawal time significantly improves the adenoma detection rate and the performance of endoscopists. Endoscopy, 2016, 48, 256-262.	1.0	45
46	How Do Gastroenterologists Assess Overall Activity of Eosinophilic Esophagitis in Adult Patients?. American Journal of Gastroenterology, 2015, 110, 402-414.	0.2	44
47	Alicaforsen, an antisense inhibitor of ICAMâ€1, as treatment for chronic refractory pouchitis after proctocolectomy: A case series. United European Gastroenterology Journal, 2016, 4, 97-104.	1.6	44
48	Expression Patterns of TNFî±, MAdCAM1, and STAT3 in Intestinal and Skin Manifestations of Inflammatory Bowel Disease. Journal of Crohn's and Colitis, 2018, 12, 347-354.	0.6	44
49	Upper Gastrointestinal Tract Involvement in Crohn's Disease: Frequency, Risk Factors, and Disease Course. Journal of Crohn's and Colitis, 2018, 12, 1399-1409.	0.6	40
50	Development of a core outcome set for therapeutic studies in eosinophilic esophagitis (COREOS). Journal of Allergy and Clinical Immunology, 2022, 149, 659-670.	1.5	40
51	Malignancies in Inflammatory Bowel Disease: Frequency, Incidence and Risk Factors—Results from the Swiss IBD Cohort Study. American Journal of Gastroenterology, 2019, 114, 116-126.	0.2	39
52	High altitude journeys and flights are associated with an increased risk of flares in inflammatory bowel disease patients. Journal of Crohn's and Colitis, 2014, 8, 191-199.	0.6	37
53	Early Initiation of Anti-TNF is Associated with Favourable Long-term Outcome in Crohn's Disease: 10-Year-Follow-up Data from the Swiss IBD Cohort Study. Journal of Crohn's and Colitis, 2019, 13, 1292-1301.	0.6	37
54	The presence of genetic risk variants within PTPN2 and PTPN22 is associated with intestinal microbiota alterations in Swiss IBD cohort patients. PLoS ONE, 2018, 13, e0199664.	1.1	35

#	Article	IF	CITATIONS
55	Heterogeneity in Clinical, Endoscopic, and Histologic Outcome Measures and Placebo Response Rates in Clinical Trials of Eosinophilic Esophagitis: A Systematic Review. Clinical Gastroenterology and Hepatology, 2018, 16, 1714-1729.e3.	2.4	33
56	The Relevance of Vitamin and Iron Deficiency in Patients with Inflammatory Bowel Diseases in Patients of the Swiss IBD Cohort. Inflammatory Bowel Diseases, 2018, 24, 1768-1779.	0.9	32
57	Eosinophilic Esophagitis: Relationship of Subepithelial Eosinophilic Inflammation With Epithelial Histology, Endoscopy, Blood Eosinophils, and Symptoms. American Journal of Gastroenterology, 2018, 113, 348-357.	0.2	32
58	The Impact of Azathioprine-Associated Lymphopenia on the Onset of Opportunistic Infections in Patients with Inflammatory Bowel Disease. PLoS ONE, 2016, 11, e0155218.	1.1	31
59	Diagnostic and Therapeutic Long-term Management of Eosinophilic Esophagitis— Current Concepts and Perspectives for Steroid Use. Clinical and Translational Gastroenterology, 2018, 9, e212.	1.3	31
60	Celiac disease diagnosis still significantly delayed – Doctor's but not patients' delay responsive for the increased total delay in women. Digestive and Liver Disease, 2016, 48, 1148-1154.	0.4	30
61	Frequency and type of drug-related side effects necessitating treatment discontinuation in the Swiss Inflammatory Bowel Disease Cohort. European Journal of Gastroenterology and Hepatology, 2018, 30, 612-620.	0.8	30
62	Update on basic and clinical aspects of eosinophilic oesophagitis. Gut, 2014, 63, 1355-1363.	6.1	29
63	Effects of oral antibiotics and isotretinoin on the murine gut microbiota. International Journal of Antimicrobial Agents, 2017, 50, 342-351.	1.1	27
64	Update on the Management of Inflammatory Bowel Disease during Pregnancy and Breastfeeding. Digestion, 2020, 101, 27-42.	1.2	27
65	New insights into the pathophysiology of inflammatory bowel disease: microbiota, epigenetics and common signalling pathways. Swiss Medical Weekly, 2018, 148, w14599.	0.8	27
66	Occurrence of skin manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. PLoS ONE, 2019, 14, e0210436.	1.1	26
67	Clinical manifestations, pathophysiology, treatment and outcome of inflammatory bowel diseases in older people. Maturitas, 2018, 110, 71-78.	1.0	25
68	Eosinophilic esophagitisâ€"established facts and new horizons. Seminars in Immunopathology, 2021, 43, 319-335.	2.8	25
69	Fatigue in inflammatory bowel disease and its impact on daily activities. Alimentary Pharmacology and Therapeutics, 2021, 53, 138-149.	1.9	25
70	Fistulizing Crohn's Disease. Clinical and Translational Gastroenterology, 2017, 8, e106.	1.3	24
71	Adults with eosinophilic oesophagitis identify symptoms and quality of life as the most important outcomes. Alimentary Pharmacology and Therapeutics, 2018, 48, 1082-1090.	1.9	24
72	Impact of obesity on disease activity and disease outcome in inflammatory bowel disease: Results from the Swiss inflammatory bowel disease cohort. United European Gastroenterology Journal, 2020, 8, 1196-1207.	1.6	24

#	Article	IF	CITATIONS
73	Orodispersible budesonide tablets for the treatment of eosinophilic esophagitis: a review of the latest evidence. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482092728.	1.4	24
74	Foodâ€induced immediate response of the esophagus—A newly identified syndrome in patients with eosinophilic esophagitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 339-347.	2.7	22
75	Pregnancy and Breastfeeding in Inflammatory Bowel Disease. Digestion, 2012, 86, 45-54.	1.2	21
76	Prediction of low bone mineral density in patients with inflammatory bowel diseases. United European Gastroenterology Journal, 2016, 4, 669-676.	1.6	21
77	Uveitis manifestations in patients of the Swiss Inflammatory Bowel Disease Cohort Study. Therapeutic Advances in Gastroenterology, 2019, 12, 175628481986514.	1.4	20
78	Depressive Symptoms Predict Clinical Recurrence of Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2022, 28, 560-571.	0.9	20
79	Effectiveness and Safety of High- vs Low-Dose Swallowed Topical Steroids for Maintenance Treatment of Eosinophilic Esophagitis: A Multicenter Observational Study. Clinical Gastroenterology and Hepatology, 2021, 19, 2514-2523.e2.	2.4	19
80	Allogeneic expanded adiposeâ€derived mesenchymal stem cell therapy for perianal fistulas in Crohn's disease: A case series. Colorectal Disease, 2021, 23, 1444-1450.	0.7	19
81	Latest Insights on the Relationship Between Symptoms and Biologic Findings in Adults with Eosinophilic Esophagitis. Gastrointestinal Endoscopy Clinics of North America, 2018, 28, 35-45.	0.6	18
82	Reliability and responsiveness of endoscopic disease activity assessment in eosinophilic esophagitis. Gastrointestinal Endoscopy, 2022, 95, 1126-1137.e2.	0.5	18
83	Medical algorithm: Diagnosis and treatment of eosinophilic esophagitis in adults. Allergy: European Journal of Allergy and Clinical Immunology, 2020, 75, 727-730.	2.7	17
84	Retrospective Analysis of Treatment and Complications of Immune Checkpoint Inhibitor-Associated Colitis: Histological Ulcerations as Potential Predictor for a Steroid-Refractory Disease Course. Inflammatory Intestinal Diseases, 2020, 5, 109-116.	0.8	17
85	Close followâ€up is associated with fewer stricture formation and results in earlier detection of histological relapse in the longâ€term management of eosinophilic esophagitis. United European Gastroenterology Journal, 2022, 10, 308-318.	1.6	17
86	Exercise-induced Chest Pain: An Atypical Manifestation of Eosinophilic Esophagitis. American Journal of Medicine, 2015, 128, 196-199.	0.6	16
87	Variation in Endoscopic Activity Assessment and Endoscopy Score Validation in Adults With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2019, 17, 1477-1488.e10.	2.4	16
88	Type D personality is associated with depressive symptoms and clinical activity in inflammatory bowel disease. Alimentary Pharmacology and Therapeutics, 2021, 54, 53-67.	1.9	16
89	The appearance of joint manifestations in the Swiss inflammatory bowel disease cohort. PLoS ONE, 2019, 14, e0211554.	1.1	15
90	Clinical Relevance of Anti-TNF Antibody Trough Levels and Anti-Drug Antibodies in Treating Inflammatory Bowel Disease Patients. Inflammatory Intestinal Diseases, 2021, 6, 1-10.	0.8	15

#	Article	IF	CITATIONS
91	Characterization of eosinophilic esophagitis variants by clinical, histological, and molecular analyses: A crossâ€sectional multiâ€enter study. Allergy: European Journal of Allergy and Clinical Immunology, 2022, 77, 2520-2533.	2.7	15
92	Patients $\hat{a} \in \mathbb{T}^{M}$ perceptions on the impact of coffee consumption in inflammatory bowel disease: friend or foe? $\hat{a} \in \mathbb{T}^{M}$ a patient survey. Nutrition Journal, 2015, 14, 78.	1.5	14
93	Alicaforsen, an Antisense Inhibitor of Intercellular Adhesion Molecule-1, in the Treatment for Left-Sided Ulcerative Colitis and Ulcerative Proctitis. Digestive Diseases, 2018, 36, 123-129.	0.8	14
94	The Vampire Study: Significant elevation of faecal calprotectin in healthy volunteers after 300 ml blood ingestion mimicking upper gastrointestinal bleeding. United European Gastroenterology Journal, 2018, 6, 1007-1014.	1.6	14
95	The Efficacy and Safety of Golimumab as Third- or Fourth-Line Anti-TNF Therapy in Patients with Refractory Crohn's Disease: A Case Series. Inflammatory Intestinal Diseases, 2017, 2, 131-138.	0.8	13
96	Pharmacologic Treatment of Eosinophilic Esophagitis. Gastrointestinal Endoscopy Clinics of North America, 2018, 28, 77-88.	0.6	12
97	Technical feasibility, clinical effectiveness, and safety of esophageal stricture dilation using a novel endoscopic attachment cap in adults with eosinophilic esophagitis. Gastrointestinal Endoscopy, 2021, 94, 912-919.e2.	0.5	12
98	Budesonide orodispersible tablets for induction of remission in patients with active eosinophilic oesophagitis: A 6â€week openâ€label trial of the EOSâ€⊋ Programme. United European Gastroenterology Journal, 2022, 10, 330-343.	1.6	11
99	What \hat{E}_4 's new in the diagnosis and therapy of eosinophilic esophagitis? Current Opinion in Gastroenterology, 2009, 25, 366-371.	1.0	10
100	Environmental Factors and Their Impact on the Intestinal Microbiota: A Role for Human Disease?. Digestive Diseases, 2012, 30, 20-27.	0.8	10
101	Risk Factors for the Development of Fistulae and Stenoses in Crohn Disease Patients in the Swiss Inflammatory Bowel Disease Cohort. Inflammatory Intestinal Diseases, 2016, 1, 172-181.	0.8	10
102	A Symptomatic Coffee Bean: Acute Sigmoid Volvulus. Case Reports in Gastroenterology, 2017, 11, 348-351.	0.3	10
103	Cohort Profile: The Swiss Eosinophilic Esophagitis Cohort Study (SEECS). Inflammatory Intestinal Diseases, 2017, 2, 163-170.	0.8	10
104	Celiac Disease is Misdiagnosed Based on Serology Only in a Substantial Proportion of Patients. Journal of Clinical Gastroenterology, 2018, 52, 25-29.	1.1	9
105	How to approach adult patients with asymptomatic esophageal eosinophilia. Ecological Management and Restoration, 2021, 34, .	0.2	9
106	A single nucleotide polymorphism in the gene for GPR183 increases its surface expression on blood lymphocytes of patients with inflammatory bowel disease. British Journal of Pharmacology, 2021, 178, 3157-3175.	2.7	9
107	Features of foodâ€induced immediate response in the esophagus (FIRE) in a series of adult patients with eosinophilic esophagitis. Allergy: European Journal of Allergy and Clinical Immunology, 2021, 76, 2893-2895.	2.7	8
108	Clinicopathologic Correlations in Eosinophilic Gastrointestinal Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2021, 9, 3258-3266.	2.0	8

#	Article	IF	Citations
109	Systematic Review of Outcome Measures Used in Observational Studies of Adults with Eosinophilic Esophagitis. International Archives of Allergy and Immunology, 2021, 182, 1169-1193.	0.9	8
110	Sex Impacts Disease Activity But Not Symptoms or Quality of Life in Adults With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2022, 20, 1729-1738.e1.	2.4	8
111	New Onset, Aggravation and Recurrence of Crohn's Disease upon Treatment with Three Different Tumor Necrosis Factor Inhibitors. Case Reports in Gastroenterology, 2015, 9, 106-112.	0.3	7
112	Genotype-Phenotype Associations of the CD-Associated Single Nucleotide Polymorphism within the Gene Locus Encoding Protein Tyrosine Phosphatase Non-Receptor Type 22 in Patients of the Swiss IBD Cohort. PLoS ONE, 2016, 11, e0160215.	1.1	7
113	Protocol for a prospective, controlled, observational study to evaluate the influence of hypoxia on healthy volunteers and patients with inflammatory bowel disease: the Altitude IBD Study. BMJ Open, 2017, 7, e013477.	0.8	7
114	Systematic Assessment of Adult Patients' Satisfaction with Various Eosinophilic Esophagitis Therapies. International Archives of Allergy and Immunology, 2020, 181, 211-220.	0.9	7
115	Genetic risk factors predict disease progression in Crohn's disease patients of the Swiss inflammatory bowel disease cohort. Therapeutic Advances in Gastroenterology, 2020, 13, 175628482095925.	1.4	7
116	Effects of anti-TNF therapy and immunomodulators on anxiety and depressive symptoms in patients with inflammatory bowel disease: a 5-year analysis. Therapeutic Advances in Gastroenterology, 2021, 14, 175628482110337.	1.4	6
117	The Way to a Man's Stomach Is Through His Heart. Gastroenterology, 2012, 142, 212-413.	0.6	5
118	Orbital Pseudotumor as a Rare Extrahepatic Manifestation of Hepatitis C Infection. Case Reports in Gastroenterology, 2016, 10, 113-119.	0.3	5
119	Low serum zinc levels predict presence of depression symptoms, but not overall disease outcome, regardless of ATG16L1 genotype in Crohn's disease patients. Therapeutic Advances in Gastroenterology, 2018, 11, 1756283X1875771.	1.4	5
120	Medical and dietary treatments in eosinophilic esophagitis. Current Opinion in Pharmacology, 2018, 43, 139-144.	1.7	5
121	Association of IBD specific treatment and prevalence of pain in the Swiss IBD cohort study. PLoS ONE, 2019, 14, e0215738.	1.1	5
122	Long-term immune-related adverse events after discontinuation of immunotherapy. Immunotherapy, 2021, 13, 735-740.	1.0	5
123	Effectiveness of golimumab in patients with ulcerative colitis: results of a real-life study in Switzerland. Therapeutic Advances in Gastroenterology, 2022, 15, 175628482210741.	1.4	5
124	Addressing current treatment challenges in Crohn's disease in real life: A physician's survey. Digestive and Liver Disease, 2014, 46, 1066-1071.	0.4	4
125	Lower Risk of B1-to-pB3-Stage Migration in Crohn's Disease Upon Immunosuppressive and Anti-TNF Treatment in the Swiss IBD Cohort Study. Digestive Diseases and Sciences, 2020, 65, 2654-2663.	1.1	4
126	Delayed hypersensitivity reaction to orodispersible budesonide in a case with eosinophilic esophagitis. BMC Gastroenterology, 2020, 20, 419.	0.8	4

#	Article	IF	CITATIONS
127	Diet and Inflammatory Bowel Disease: What Quality Standards Should Be Applied in Clinical and Laboratory Studies?. Molecular Nutrition and Food Research, 2021, 65, e2000514.	1.5	4
128	The impact of colectomy on the course of extraintestinal manifestations in Swiss inflammatory bowel disease cohort study patients. United European Gastroenterology Journal, 2021, 9, 773-780.	1.6	4
129	Complete Recovery of Immune Checkpoint Inhibitor–induced Colitis by Diverting Loop Ileostomy. Journal of Immunotherapy, 2020, 43, 145-148.	1.2	4
130	The perspective of celiac disease patients on emerging treatment options and non-celiac gluten sensitivity. Digestive and Liver Disease, 2017, 49, 268-272.	0.4	3
131	Editorial: antiâ€TNF therapy—a doubleâ€edged sword?. Alimentary Pharmacology and Therapeutics, 2019, 50, 822-823.	1.9	3
132	The Influence of Breastfeeding, Cesarean Section, Pet Animals, and Urbanization on the Development of Inflammatory Bowel Disease: Data from the Swiss IBD Cohort Study. Inflammatory Intestinal Diseases, 2020, 5, 170-179.	0.8	3
133	Disease Progression and Outcomes of Pregnancies in Women With Eosinophilic Esophagitis. Clinical Gastroenterology and Hepatology, 2020, 18, 2456-2462.	2.4	2
134	Effect of distance to specialist care for the diagnosis and disease outcome of inflammatory bowel disease in the Swiss inflammatory bowel disease cohort study. Therapeutic Advances in Gastroenterology, 2020, 13, 175628481989521.	1.4	2
135	Lifting the Veil: The Quest for Noninvasive Biomarkers for the Accurate Diagnosis of Eosinophilic Esophagitis. Digestive Diseases and Sciences, 2021, 66, 1388-1389.	1.1	2
136	Defer No Time, Delays Have Dangerous Ends (William Shakespeare). Gastroenterology, 2021, 161, 42-44.	0.6	2
137	Salll8 - Eosinophilic Esophagitis-Like Disease with Lack of Significant Esophageal Eosinophilia: Description of a New Disease Entity. Gastroenterology, 2018, 154, S-246.	0.6	1
138	Reply. Clinical Gastroenterology and Hepatology, 2019, 17, 2385-2386.	2.4	1
139	Protein-losing enteropathy as precursor of inflammatory bowel disease: a review of the literature. BMJ Case Reports, 2021, 14, e238802.	0.2	1
140	Perianal fistulodesis – A pilot study of a novel minimally invasive surgical and medical approach for closure of perianal fistulae. World Journal of Gastrointestinal Surgery, 2021, 13, 187-197.	0.8	1
141	Higher educational level in patients with eosinophilic esophagitis: a comparative analysis. Ecological Management and Restoration, 2021, 34, .	0.2	1
142	Nutcracker Esophagus. New England Journal of Medicine, 2013, 368, e25.	13.9	0
143	Reply. Gastroenterology, 2014, 146, 1426-1427.	0.6	0
144	Vancomycin in Very-Early Onset Inflammatory Bowel Disease-Dysbiosis: Fight Fire with Fire?. Digestion, 2017, 95, 327-328.	1.2	0

#	Article	IF	CITATIONS
145	Is There a Role for Topical Swallowed Steroids upon Emergency Room Admission for Suspected Food Bolus Obstruction in Eosinophilic Esophagitis?. Dysphagia, 2021, , 1.	1.0	O
146	Genotype-phenotype associations of polymorphisms within the gene locus of NOD-like receptor pyrin domain containing 3 in Swiss inflammatory bowel disease patients. BMC Gastroenterology, 2021, 21, 310.	0.8	0